Nicotine pouches have quickly become one of the most debated products in the nicotine space. 

Depending on who you ask, they are either: 

• a dangerous new public health threat, 
• a smoking cessation tool, 
• a lower-risk nicotine alternative, 
• or simply the latest target in the broader nicotine policy war. 

But beneath the headlines and political rhetoric, an important question remains: 

What does the actual evidence say? 

The science surrounding nicotine pouches is still evolving, and long-term epidemiological data will take years to fully develop. However, a growing body of peer-reviewed research is beginning to paint a clearer picture regarding toxicant exposure, relative risk, consumer behavior, and potential public health impact. 

And while the evidence does not suggest nicotine pouches are harmless, it increasingly suggests they differ dramatically from combustible cigarettes in ways that matter for adult smokers. 

What Are Nicotine Pouches? 

Nicotine pouches are small oral pouches placed between the gum and lip that deliver nicotine without combustion and without tobacco leaf. 

Unlike cigarettes: 

• there is no smoke, 
• no tar, 
• no combustion, 
• and no carbon monoxide. 

Most nicotine pouches contain pharmaceutical-grade nicotine, plant-based fibers, flavoring, sweeteners, and stabilizing ingredients. 

Popular brands include: 

• ZYN 
• Sesh 
• ZIMO 
• Lucy 

Because they eliminate combustion entirely, researchers increasingly evaluate nicotine pouches through a tobacco harm reduction framework rather than treating them as equivalent to cigarettes. 

That distinction matters. 

According to the U.S. Centers for Disease Control and Prevention, smoking-related disease is primarily caused not by nicotine itself, but by inhalation of toxic chemicals generated through combustion. 

That is why scientists increasingly focus on relative risk rather than simplistic “safe vs dangerous” comparisons. 

Combustion Is the Real Problem 

Combustible cigarettes expose smokers to more than 7,000 chemicals, including dozens of known carcinogens. (CDC) 

This is where nicotine pouches fundamentally differ. 

Because nicotine pouches involve no burning or inhalation, users avoid exposure to: 

• tar, 
• carbon monoxide, 
• combustion particulates, 
• and thousands of smoke-related toxicants. 

A growing number of toxicological studies now show nicotine pouches expose users to dramatically fewer harmful constituents than cigarettes. 

What Biomarker Studies Show 

One of the strongest areas of emerging evidence involves biomarker research. 

Biomarkers measure exposure to harmful chemicals inside the body. 

A 2025 study examining adults who switched completely from cigarettes to nicotine pouches found reductions in biomarkers of exposure ranging from 42% to 96% within only seven days. 

Researchers observed significant reductions across multiple harmful smoke-related toxicants associated with cardiovascular disease, respiratory disease, and cancer risk. 

Other studies have similarly found: 

• lower levels of tobacco alkaloids, 
• dramatically reduced heavy metal exposure, 
• and near-undetectable levels of tobacco-specific nitrosamines (TSNAs), among the most important carcinogens associated with tobacco use. 

This does not mean nicotine pouches are “healthy.” 

But it does strongly suggest they expose users to substantially fewer harmful chemicals than smoking combustible cigarettes. 

The FDA Has Already Authorized Several Nicotine Pouches 

One fact often missing from public discussions is that the FDA has already authorized multiple nicotine pouch products through the Premarket Tobacco Product Application (PMTA) process. 

In January 2025, the FDA granted marketing orders for 20 ZYN nicotine pouch products after reviewing scientific evidence related to toxicology, abuse liability, and population health impact. 

The FDA stated that: 

“The data show that these nicotine pouch products meet the public health standard required by law.” 

The agency specifically noted that: 

• the products contain fewer harmful constituents than cigarettes, 
• adult smokers may completely switch, 
• and youth usage patterns would continue to be monitored closely. 

That authorization does not mean nicotine pouches are risk-free. 

But it does represent an important acknowledgment from federal regulators that non-combustible nicotine products may present lower risk compared with cigarettes. 

The Polosa, Fagerström, and Rodu Review 

One of the most widely discussed scientific reviews on nicotine pouches was published in 2025 by tobacco harm reduction researchers: 

• Riccardo Polosa 
• Karl Fagerström 
• Brad Rodu 

Their paper, The Emerging Role of Oral Nicotine Pouches in Tobacco Harm Reduction, reviewed toxicology, behavioral science, public health implications, and regulatory considerations. 

The researchers concluded that nicotine pouches: 

• eliminate combustion exposure, 
• substantially reduce carcinogen exposure, 
• and may play a meaningful role in reducing smoking-related disease among adults unable or unwilling to quit nicotine entirely. 

Importantly, the authors also emphasized that nicotine pouches should not be evaluated using the unrealistic standard of being entirely harmless. 

Instead, they argued products should be compared against the risks of continued smoking. 

That is the central principle of tobacco harm reduction. 

What Clinical Trials Have Found 

Clinical evidence is still limited, but early findings are notable. 

A 2025 randomized controlled trial examining smokers using 4mg nicotine pouches found participants reduced cigarette consumption from roughly 15 cigarettes per day to just over eight cigarettes daily during the study period. 

Researchers also reported: 

• reduced nicotine dependence scores, 
• improved smoking reduction outcomes, 
• and no serious adverse events. 

The most reported side effects included: 

• mild throat irritation, 
• headache, 
• and cough. 

While larger studies are still needed, these findings suggest nicotine pouches may help some smokers reduce or replace cigarette use. 

What the Cochrane Review Found 

One of the most influential evidence reviews in medicine comes from the Cochrane collaboration. 

In 2025, Cochrane published its first major review examining nicotine pouches for smoking cessation and harm reduction.

Researchers reviewed randomized controlled trials involving adult smokers and concluded: 

• nicotine pouch users showed lower exposure to harmful toxicants compared with smokers, 
• carbon monoxide exposure declined, 
• and no serious short-term health harms were identified in available studies. 

The review did not conclude nicotine pouches were ineffective. 

Instead, researchers emphasized that evidence remains limited because current studies are relatively small and short-term. 

That nuance matters. 

Many headlines framed the review as inconclusive or negative when the actual conclusion was simply that more large-scale evidence is still needed. 

Nicotine Isn’t the Same as Smoking 

One of the biggest public misconceptions is the belief that nicotine itself causes most smoking-related disease. 

But many major health organizations acknowledge that combustion is the primary driver of smoking harm. 

The UK Office for Health Improvement and Disparities has repeatedly stated that smoke-free nicotine products are substantially lower risk than cigarettes. 

Even the FDA itself acknowledges that nicotine exists on a continuum of risk. 

That does not mean nicotine is entirely benign: 

• it can increase heart rate and blood pressure, 
  
• and it is not appropriate for youth or non-users. 

But equating nicotine pouches with combustible smoking ignores major toxicological differences recognized across the scientific literature. 

Sweden May Offer the Most Important Real-World Evidence 

No discussion about oral nicotine products is complete without discussing Sweden. 

Sweden is now considered the first European nation to reach official “smoke-free” status, defined as smoking prevalence below 5%. 

Researchers widely attribute this success in part to the adoption of lower-risk oral nicotine products, particularly snus. 

While nicotine pouches are not identical to snus, they share several key characteristics: 

• oral administration, 
• no combustion, 
• and dramatically lower toxicant exposure than cigarettes. 

Sweden now has: 

• among the lowest smoking rates in Europe, 
• lower tobacco-related mortality, 
• and significantly lower rates of smoking-related cancers among men compared with many other European countries. 

That real-world evidence has become increasingly difficult for policymakers to ignore. 

Critics Still Raise Legitimate Concerns 

Despite encouraging evidence regarding relative risk, concerns remain. 

Critics point to: 

• youth uptake, 
• nicotine addiction, 
• aggressive marketing, 
• flavor availability, 
• and the lack of decades-long epidemiological data. 

Those concerns are not entirely unreasonable. 

Any responsible regulatory framework should: 

• restrict youth access, 
• enforce age verification, 
• require manufacturing standards, 
• and ensure truthful marketing. 

But many scientists argue that these concerns should be balanced against the risks of continued smoking among adults. 

That balance is where many nicotine policy debates become politically contentious. 

The Core Question Policymakers Must Answer 

The real policy question is not: 

“Are nicotine pouches perfectly safe?” 

Almost nothing is. 

The more important question is: 

“How do nicotine pouches compare to continued smoking?” 

And increasingly, the evidence suggests they are substantially lower risk than combustible cigarettes. 

That does not make them harmless. 

But it also does not support treating them as equivalent to smoking. 

As the science continues to evolve, policymakers face an important challenge: 

building regulations that acknowledge both uncertainty and relative risk. 

Because if adult smokers are going to continue using nicotine — and millions will — the difference between combustion and non-combustion may ultimately matter far more than many public discussions currently acknowledge.